HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

UC2288

a p21 attenuator structurally related to sorafenib

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Liang, Renba: 1 article (01/2021)
2.	Zhu, Xiaodong: 1 article (01/2021)
3.	Hammock, Bruce D: 1 article (03/2013)
4.	Hee Hwang, Sung: 1 article (03/2013)
5.	Li, Cuiwen: 1 article (03/2013)
6.	Shiu, Eunice Y: 1 article (03/2013)
7.	Wecksler, Aaron T: 1 article (03/2013)
8.	Weiss, Robert H: 1 article (03/2013)
9.	Wettersten, Hiromi I: 1 article (03/2013)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "However, studies about the effects of UC2288 on tumors are few. " 03/01/2013 - "In addition, UC2288 inhibits cell growth in the kidney cancer cell lines (GI50 = approximately 10 µM) as well as multiple other cancer cell lines. "
2.	Neuroblastoma 01/01/2022 - "Furthermore, the neuroblastoma cell lines showed high sensitivity to UC2288, and combination treatment with cisplatin resulted in considerably decreased cell viability and delay in regrowth in the two most resistant cell lines, SK-N-DZ and BE(2)-C. "
3.	Kidney Neoplasms (Kidney Cancer) 03/01/2013 - "In addition, UC2288 inhibits cell growth in the kidney cancer cell lines (GI50 = approximately 10 µM) as well as multiple other cancer cell lines. "
4.	Fibrosis (Cirrhosis) 01/01/2023 - "Inhibition of p21 by UC2288 compromised the elevation of lens fibrosis markers in miR-184-/- lenses. "
5.	Nasopharyngeal Carcinoma 01/01/2021 - "UC2288 induces cell apoptosis of nasopharyngeal carcinoma cells via inhibiting EGFR/ERK pathway."

Related Drugs and Biologics

1.	Cisplatin (Platino)

Related Therapies and Procedures

1.	Lenses